Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

(Circulation. 2010;121:833-840.)


© 2010 American Heart Association, Inc.
--------------------------------------------------------------------------------

AHA/ACS/AUA Science Advisory

Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology

Glenn N. Levine, MD, FAHA, Chair; Anthony V. D'Amico, MD, PhD; Peter Berger, MD, FAHA; Peter E. Clark, MD; Robert H. Eckel, MD, FAHA; Nancy L. Keating, MD, MPH; Richard V. Milani, MD, FAHA; Arthur I. Sagalowsky, MD; Matthew R. Smith, MD, PhD; Neil Zakai, MD, on behalf of the American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association



Key Words: AHA Scientific Statements • cardiovascular risk • prostate cancer • androgen-deprivation therapy





An extract of the first 250 words of the full text is provided, because this article has no abstract.











Introduction



Androgen-deprivation therapy (ADT) is a widely used treatment for prostate cancer. Recently, several studies have reported an association between ADT and an increased risk of cardiovascular events, including myocardial infarction and cardiovascular mortality.1–5 These reports have led to increased interest and discussion regarding the metabolic effects of ADT and its possible association with increased cardiovascular risk. In addition, likely as a result of these reports, internists, endocrinologists, and cardiologists are now being consulted regarding the evaluation and management of patients in whom ADT is being initiated. Most of these physicians are not aware of the possible effects of ADT on cardiovascular risk factors or the issues regarding ADT and cardiovascular disease. Therefore, this multidisciplinary writing group has been commissioned to review and summarize the metabolic effects of ADT, to evaluate the data regarding a possible relationship between ADT and cardiovascular events in patients with prostate cancer, and to generate suggestions regarding the evaluation and management of patients, both with and without known cardiac disease, in whom ADT is being initiated.

The writing group emphasizes that the purpose of this advisory is strictly informative. This advisory should thus not be construed as dictating clinical practice or superseding the clinical judgment of physicians, and it should not be used for medicolegal purposes./.../